EUVIMEDEUVIMED entdecken
Crossref

Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.

Amy Logan, Christopher B Howard, Pie Huda, Kathleen Kimpton, Zerong Ma, Kristofer J Thurecht, Joshua A McCarroll, Ernest Moles, Maria Kavallaris

Journal of Controlled Release · 2024

DOI: 10.1016/j.jconrel.2024.02.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Amy Logan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW 2052, Australia; UNSW Australian Centre for Nanomedicine, Faculty of Engi…. Hauptthemen laut MEDLINE: Neuroblastoma, Nanoparticles. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-risk neuroblastoma has poor survival due to treatment failure and off-target side effects of therapy. Small molecule inhibitors have shown therapeutic efficacy at targeting oncogenic cell cycle dysregulators, such as polo-like kinase 1 (PLK1). However, their clinical success is limited by a lack of efficacy and specificity, causing off-target toxicity. Herein, we investigate a new treatment strategy whereby a bispecific antibody (BsAb) with dual recognition of methoxy polyethylene glycol (PEG) and a neuroblastoma cell-surface receptor, epidermal growth factor receptor (EGFR), is combined with a PEGylated small interfering RNA (siRNA) lipid nanoparticle, forming BsAb-nanoparticle RNA-interference complexes for targeted PLK1 inhibition against high-risk neuroblastoma. Therapeutic efficacy of this strategy was explored in neuroblastoma cell lines and a tumor xenograft model. Using ionizable lipid-based nanoparticles as a low-toxicity and clinically safe approach for siRNA delivery, we identified that their complexing with EGFR-PEG BsAb resulted in increases in cell targeting (1.2 to >4.5-fold) and PLK1 gene silencing (>2-fold) against EGFR+ high-risk neuroblastoma cells, and enhancements correlated with EGFR expression on the cells (r > 0.94). Through formulating nanoparticles with PEG-lipids ranging in diffusivity, we further identified a highly diffusible PEG-lipid which provided the most pronounced neuroblastoma cell binding, PLK1 silencing, and significantly reduced cancer growth in vitro in high-risk neuroblastoma cell cultures and in vivo in a tumor-xenograft mouse model of the disease. Together, this work provides an insight on the role of PEG-lipid diffusivity and EGFR targeting as potentially relevant variables influencing the therapeutic efficacy of siRNA nanoparticles in high-risk neuroblastoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeuroblastomaNanoparticlesHumansAnimalsMiceRNA, Small InterferingProtein Serine-Threonine KinasesCell Cycle ProteinsPolo-Like Kinase 1Polyethylene GlycolsProto-Oncogene ProteinsCell Line, TumorErbB ReceptorsCell ProliferationLipids

Stichwörter der Autor:innen

Bispecific antibodiesEGFR targetingLipid nanoparticlesNeuroblastoma therapyPolo-like kinase 1 silencingTargeted siRNA delivery

Substanzen

RNA, Small InterferingProtein Serine-Threonine KinasesCell Cycle ProteinsPolo-Like Kinase 1Polyethylene GlycolsProto-Oncogene ProteinsErbB ReceptorsLipidsEGFR protein, human

Autor:innen und Institutionen

  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW 2052, Australia; UNSW Australian Centre for Nanomedicine, Faculty of Engineering, UNSW, Sydney, NSW 2052, Australia; School of Clinical Medicin…
  • Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, QLsD, 4072, Australia.
  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW, Sydney, NSW 2052, Australia; School of Clinical Medicine, Faculty of Medicine & Health, UNSW, Sydney, NSW 2052, Australia.
  • Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, St Lucia, QLsD, 4072, Australia; Centre for Advanced Imaging, ARC Training Centre for Innovation in Biomedical Imaging Tec…

Zitieren

APA

Logan, A., Howard, C. B., Huda, P., Kimpton, K., Ma, Z., Thurecht, K. J., McCarroll, J. A., Moles, E., & Kavallaris, M. (2024). Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.02.007

Vancouver

Logan A, Howard CB, Huda P, Kimpton K, Ma Z, Thurecht KJ, et al. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.02.007

BibTeX
@article{Logan2024,
  author = {Logan, Amy and Howard, Christopher B and Huda, Pie and Kimpton, Kathleen and Ma, Zerong and Thurecht, Kristofer J and McCarroll, Joshua A and Moles, Ernest and Kavallaris, Maria},
  title = {Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma},
  journal = {Journal of Controlled Release},
  year = {2024},
  doi = {10.1016/j.jconrel.2024.02.007}
}
Kostenlos starten →